drugset / Trial / NCT06817577
NG004 in Spinal Cord Injury Patients
NaSingle-groupOpen-labelTreatment
Summary
This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI. The trial will evaluate the safety, tolerability, and PK of 4 dose regimens of NG004, and will evaluate the maximum tolerated dose of NG004.
Timeline
- Start
- 2024-12-18
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NG004 | Monoclonal antibody | — | Intrathecal |